Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.36 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.34 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8198281 | 0.75 | SMN1; SMN2 (0.42) | SMN1; SMN2HIF1ACYP1A2CYP2D6GRM2 | |
| SCHEMBL9636355 | 0.73 | ACE (0.40) | SMN1; SMN2HIF1ACYP1A2CYP2D6GRM2 | |
| SCHEMBL29436998 | 0.71 | HPGD (0.50) | SMN1; SMN2HIF1ACYP2D6ALOX5 | |
| SCHEMBL5941281 | 0.71 | SMN1; SMN2 (0.46) | SMN1; SMN2HIF1AACELAP3 | |
| SCHEMBL11213498 | 0.69 | GRM2 (0.40) | SMN1; SMN2HIF1AGRM2GRM3 | |
| SCHEMBL13270955 | 0.69 | CYP2C19 (0.51) | SMN1; SMN2CYP1A2CYP2D6GABBR2GABBR1 | |
| SCHEMBL28062037 | 0.69 | MTNR1A (0.47) | CYP2D6ACEGABBR2GABBR1 | |
| SCHEMBL1171114 | 0.69 | GABBR2 (0.53) | CYP2D6GABBR2GABBR1 | |
| SCHEMBL27924822 | 0.67 | GAA (0.44) | SMN1; SMN2HIF1ACYP1A2CYP2D6GAA | |
| Hydrogen Sulfide SCHEMBL28282419 | 0.67 | GABBR2 (0.52) | CYP2D6GABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079495-A1 | Diagnosis and treatment system for \"reward deficiency syndrome\" (RDS) and related behaviors | SYNAPTAMINE, INC. | 2006-04-13 | — | — | US | disclosed |
| US-6955873-B1 | Diagnosis and treatment system for reward deficiency syndrome (RDS) and related behaviors | SYNAPTAMINE, INC. | 2005-10-18 | — | — | US | disclosed |
| US-6132724-A | Allelic polygene diagnosis of reward deficiency syndrome and treatment | CITY OF HOPE NATIONAL MEDICAL CENTER (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0979092-A2 | ALLELIC POLYGENE DIAGNOSIS OF REWARD DEFICIENCY SYNDROME AND TREATMENT | Kenneth Blum, Inc. (US) | 2000-02-16 | — | — | EP | disclosed |
| WO-1998048785-A9 | ALLELIC POLYGENE DIAGNOSIS OF REWARD DEFICIENCY SYNDROME AND TREATMENT | KENNETH BLUM INC (US) | 1999-05-20 | — | — | WO | disclosed |
| WO-1998048785-A2 | ALLELIC POLYGENE DIAGNOSIS OF REWARD DEFICIENCY SYNDROME AND TREATMENT | KENNETH BLUM, INC. (US) | 1998-11-05 | — | — | WO | disclosed |
| EP-0381696-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF COCAINE ADDICTION | MATRIX TECHNOLOGIES, INC. (US) | 1993-07-28 | — | — | EP | disclosed |
| US-5189064-A | Administering enkephalinase inhibitor and neurotransmitter precursor | MATRIX TECHNOLOGIES, INC. (US) | 1993-02-23 | — | — | US | disclosed |
| EP-0381696-A4 | TREATMENT OF COCAINE ADDICTION | — | 1990-10-10 | — | — | EP | disclosed |
| EP-0381696-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF COCAINE ADDICTION. | MATRIX TECHNOLOGIES INC (US) | 1990-08-16 | — | — | EP | disclosed |
| WO-1989003211-A1 | TREATMENT OF COCAINE ADDICTION | MATRIX TECHNOLOGIES, INCORPORATED (US) | 1989-04-20 | — | — | WO | disclosed |
| US-4761429-A | ALCOHOL CRAVING | BIESER, ALBERT H. | 1988-08-02 | — | — | US | disclosed |